APG-1252 was designed to reduce the target platelet toxicity seen with dual inhibitors Bcl-2/Bcl-xL, while maintaining strong antitumor activity.
Preliminary results showed that APG-1252 was well-tolerated with no hematologic toxicity reported. There was one confirmed partial response in a metastatic small cell lung cancer (SCLC) patient. Dose escalation continues in SCLC and other solid tumors.
APG-1387, an IAP inhibitor, was well-tolerated with manageable adverse events. Preliminary responses indicated positive host immune responses, suggesting synergy with immunotherapy agents.
Studies are continuing with APG-1387 in combination with immunotherapy agents in patients with advanced solid tumors or hematologic malignancies.
Ascentage Pharma is dedicated to developing apoptosis-targeted small molecule therapies for cancers, hepatitis B, and age-related diseases.
The company's expertise is in designing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death.
It has a pipeline of seven clinical candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, APG-1252, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886